Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.

Huang ZH, Shi L, Ma JW, Sun ZY, Cai H, Chen YX, Zhao YF, Li YM.

J Am Chem Soc. 2012 May 30;134(21):8730-3. doi: 10.1021/ja211725s. Epub 2012 May 17.

PMID:
22587010
2.

Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.

Wilkinson BL, Day S, Chapman R, Perrier S, Apostolopoulos V, Payne RJ.

Chemistry. 2012 Dec 14;18(51):16540-8. doi: 10.1002/chem.201202629. Epub 2012 Oct 22.

PMID:
23090901
3.
4.

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF.

Vaccine. 2000 Apr 3;18(19):2059-71.

PMID:
10706970
5.

Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.

Sarkar S, Salyer AC, Wall KA, Sucheck SJ.

Bioconjug Chem. 2013 Mar 20;24(3):363-75. doi: 10.1021/bc300422a. Epub 2013 Mar 8.

6.

Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.

Sørensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H.

Glycobiology. 2006 Feb;16(2):96-107. Epub 2005 Oct 5.

PMID:
16207894
7.

T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.

Pisarev VM, Kinarsky L, Caffrey T, Hanisch FG, Sanderson S, Hollingsworth MA, Sherman S.

Int Immunopharmacol. 2005 Feb;5(2):315-30.

PMID:
15652762
9.

Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen.

Schuman J, Campbell AP, Koganty RR, Longenecker BM.

J Pept Res. 2003 Mar;61(3):91-108.

PMID:
12558945
10.

Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.

Hanisch FG, Ninkovic T.

Curr Protein Pept Sci. 2006 Aug;7(4):307-15. Review.

PMID:
16918445
11.

First self-adjuvant multicomponent potential vaccine candidates by tethering of four or eight MUC1 antigenic immunodominant PDTRP units on a calixarene platform: synthesis and biological evaluation.

Geraci C, Consoli GM, Granata G, Galante E, Palmigiano A, Pappalardo M, Di Puma SD, Spadaro A.

Bioconjug Chem. 2013 Oct 16;24(10):1710-20. doi: 10.1021/bc400242y. Epub 2013 Sep 16.

PMID:
24041198
12.

Design of a MUC1-based cancer vaccine.

Hanisch FG.

Biochem Soc Trans. 2005 Aug;33(Pt 4):705-8.

PMID:
16042579
13.

Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.

Cai H, Sun ZY, Chen MS, Zhao YF, Kunz H, Li YM.

Angew Chem Int Ed Engl. 2014 Feb 3;53(6):1699-703. doi: 10.1002/anie.201308875. Epub 2014 Jan 21.

PMID:
24449389
14.

Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.

Wilkinson BL, Day S, Malins LR, Apostolopoulos V, Payne RJ.

Angew Chem Int Ed Engl. 2011 Feb 11;50(7):1635-9. doi: 10.1002/anie.201006115. Epub 2011 Jan 7. No abstract available.

PMID:
21308921
15.

Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.

Zhang S, Zhang H, Shi H, Yu X, Kong W, Li W.

Hum Immunol. 2008 Apr-May;69(4-5):250-8. doi: 10.1016/j.humimm.2008.02.006. Epub 2008 Apr 4.

PMID:
18486759
16.

Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.

Schuman JT, Grinstead JS, Apostolopoulos V, Campbell AP.

Biopolymers. 2005 Feb 5;77(2):107-20.

PMID:
15635690
17.

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ.

Proc Natl Acad Sci U S A. 2012 Jan 3;109(1):261-6. doi: 10.1073/pnas.1115166109. Epub 2011 Dec 14.

18.

Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.

Tarp MA, Sørensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H.

Glycobiology. 2007 Feb;17(2):197-209. Epub 2006 Oct 18.

PMID:
17050588
19.

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

Tsang KY, Palena C, Gulley J, Arlen P, Schlom J.

Clin Cancer Res. 2004 Mar 15;10(6):2139-49.

20.

Synthetic glycopeptides for the development of cancer vaccines.

Liakatos A, Kunz H.

Curr Opin Mol Ther. 2007 Feb;9(1):35-44. Review.

PMID:
17330400

Supplemental Content

Support Center